Form 4 for AURA Aura Biosciences, Inc.
Accepted 2026-09-01 17:21:45 ET · period of report 2026-09-01 · accession 0002148701-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-01 17:21 | 2026-09-01 | AURA | Abu-Absi Susan | COO | A - Grant | $0.00 | +134.5K | 134.5K | New | $0 |
| D | 2026-09-01 17:21 | 2026-09-01 | AURA | Abu-Absi Susan | COO | A - Grant | $0.00 | +265.5K | 265.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-01 | A | A | 134,513 | $0.00 | 134,513 | D | — | — | (F1) These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-09-01 | A | A | 265,487 | $0.00 | 265,487 | D | $7.43 · — to 2036-09-01 | 265,487 Common Stock | (F2) The option shall vest as follows: 25% of the options vest on August 10, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |